CD-38 directed chimeric antigen receptor constructs

Patent metadata

Field	Value
Publication number	US-11760806-B2
Application number	US-201816179850-A
Country	US
Kind code	B2
Filing date	Nov 2, 2018
Priority date	Nov 3, 2017
Publication date	Sep 19, 2023
Grant date	Sep 19, 2023

Abstract

There is disclosed compositions and methods relating to or derived from anti-CD38 antibodies. More specifically, there is disclosed fully human antibodies that bind CD38, CD38-antibody binding fragments and derivatives of such antibodies, and CD38-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.

First claim

We claim:

1. A host cell, or a population of host cells, which express an anti-CD38 chimeric antigen receptor (CAR) construct comprising:
i) an antigen binding protein that binds to CD38, wherein the antigen binding protein is an scFv antibody comprising a heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO: 3;
ii) a transmembrane domain; and
iii) an intracellular domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 9 and an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 10,
wherein the host cell or population of host cells are transduced with an expression vector operably linked to a nucleic acid encoding the anti-CD38 CAR construct, and
wherein the expression vector directs expression of the anti-CD38 CAR construct in the host cell;

wherein the host cell is a wild-type-CD38-expressing T host cell or a wild-type-CD38-expressing natural killer host cell or the population of host cells is a wild-type-CD38-expressing population of T host cells or a wild-type-CD38-expressing population of natural killer host cells.

2. A host cell, or a population of host cells, which express an anti-CD38 chimeric antigen receptor (CAR) construct which comprises:
i) an antigen binding protein that binds to CD38, wherein the antigen binding protein is an scFv antibody comprising a heavy chain variable (VH) domain comprising the CDRs set forth in the amino acid sequence of SEQ ID NO: 1 and a light chain variable (VL) domain comprising the CDRs set forth in the amino acid sequence of SEQ ID NO: 3;
ii) a transmembrane domain; and
iii) an intracellular domain,
wherein the host cell or population of host cells are transduced with an expression vector operably linked to a nucleic acid encoding the anti-CD38 CAR construct, and
wherein the expression vector directs expression of the anti-CD38 chimeric CAR construct in the host cell;

wherein the host cell is a wild-type-CD38-expressing T host cell or a wild-type-CD38-expressing natural killer host cell or the population of host cells is a wild-type-CD38-expressing population of T host cells or a wild-type-CD38-expressing population of natural killer host cells.

3. The host cell or population of host cells of claim 1 or 2 , wherein the expression vector comprises a retroviral expression vector.

4. The host cell or population of host cells of claim 1 or 2 , wherein the natural killer host cell or the population of natural killer host cells is a placental derived natural killer host cell or a population thereof, or a cord blood derived natural killer host cell or a population thereof.

5. The host cell or population of host cells of claim 1 or 2 , wherein the anti-CD38 chimeric antigen receptor (CAR) construct further comprises a peptide linker between the heavy chain variable (VH) domain and the light chain variable (VL) domain, wherein the peptide linker comprises the amino acid sequence of SEQ ID NO: 5.

6. The host cell or population of host cells of claim 1 , wherein the antigen binding protein comprises the amino acid sequence of SEQ ID NO: 12.

7. The host cell or population of host cells of claim 1 or 2 , wherein the anti-CD38 chimeric antigen receptor (CAR) construct further comprises a hinge region between the antigen binding protein and the transmembrane domain, wherein the hinge region is a CD8 hinge region comprising the amino acid sequence of SEQ ID NO. 6.

8. The host cell or population of host cells of claim 1 , wherein the anti-CD38 chimeric antigen receptor (CAR) construct further comprises a CD28 extracellular domain between the antigen binding protein and the transmembrane domain, wherein the CD28 extracellular domain comprises the amino acid sequence of SEQ ID NO: 7.

9. The host cell or population of host cells of claim 1 or 2 , wherein the transmembrane domain is a CD28 transmembrane domain which comprises the amino acid sequence of SEQ ID NO: 8.

10. The host cell or population of host cells of claim 1 or 2 , wherein the intracellular domain comprises a CD28 intracellular domain which comprises the amino acid sequence of SEQ ID NO:9 and a CD3-zeta intracellular domain which comprises the amino acid sequence of SEQ ID NO:10.

11. The host cell or population of host cells of claim 1 , wherein the anti-CD38 chimeric antigen receptor (CAR) construct comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 20.

12. The host cell or population of host cells of claim 1 or 2 , wherein the anti-CD38 chimeric antigen receptor (CAR) construct further comprises a hinge region between the antigen binding protein and the transmembrane domain, wherein the hinge region is chosen from a CD8 hinge region and a CD8a hinge region.

13. The host cell or population of host cells of claim 1 or 2 , wherein the anti-CD38 chimeric antigen receptor (CAR) construct further comprises a hinge region between the antigen binding protein and the transmembrane domain, wherein the hinge region is a CD8 hinge region comprising the amino acid sequence of SEQ ID NO. 17.

14. The host cell or population of host cells of claim 1 or 2 , wherein the transmembrane domain is a transmembrane domain of a protein chosen from alpha chain of T-cell receptor, beta chain of T-cell receptor, zeta chain of T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, LFA-1 T-cell co-receptor, CD2 T-cell co-receptor/adhesion molecule, and CD8 alpha.

15. The host cell or population of host cells of claim 2 , wherein the intracellular domain is an intracellular domain of a protein chosen from CD3-zeta, 4-1BB, and a CD28.

16. The host cell or population of host cells of claim 1 or 2 , wherein the intracellular domain comprises a co-stimulatory signaling domain of a protein chosen from CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, and B7-H3.

17. The host cell or population of host cells of claim 1 or 2 , wherein the anti-CD38 chimeric antigen receptor (CAR) construct further comprises a signal sequence, wherein the signal sequence is a signal sequence of a protein chosen from CD8a, CD28, and CD16.

18. The host cell or population of host cells of claim 1 or 2 , wherein the host cell or population of host cells exhibits limited fratricide activity.

Assignees

• Sorrento Therapeutics Inc

Inventors

• Zhang Yanliang
• Zhou Heyue
• Ma Qianzhong

Classifications

• A61K40/4222

  CD38 not IgG · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/48

  Blood cells, e.g. leukemia or lymphoma · CPC title

• A61K2239/31

  characterized by the route of administration · CPC title